The αvβ3-dependent anticancer properties of tetrac are related to the regulation of cancer biology-relevant gene expression implicated in multiple cancer growth and survival-promoting pathways: Genes whose products control apoptosis, cell cycle and proliferation, survival pathway components, and angiogenesis.22–24 Notably, antiangiogenic agents such as bevacizumab that are targeted to a single vascular growth factor, such as VEGF, have improved 6-month progression-free survival in GBM, but not overall survival.25 This evidence concerns the gene VEGFA and cancer.